Restoring Biological Harmony for Patients with Debilitating Disease
We are harnessing the power of microRNA science to develop therapies that normalize biological pathways and counterbalance disease.
Learn More
DEVELOPMENT PROGRAMS
Our pipeline is focused on serious diseases of high unmet need where the latest discoveries in microRNA biology are challenging traditional drug development paradigms and creating opportunities for novel therapeutic approaches.
Recent Press Releases
- miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update
- miRagen Therapeutics to Report First Quarter 2020 Financial Results On May 7, 2020
- miRagen Reports Fourth Quarter and Full Year 2019 Financial Results
- miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020
- miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock